MarketPR

Starling Oncology taps SLR Healthcare ABL for $25 million revolving facility, draws $4.75 million at close

8/22/2026

A $25 million revolving credit facility, priced at Term SOFR plus 3.95 percent and maturing August 20, 2029, is now in place at Starling Oncology, Inc.

(Nasdaq: STLN) after its operating subsidiary closed the arrangement with Gemino Healthcare Finance, LLC on August 21, 2026. The direct borrower is Starling Oncology Management, LLC.

At closing, $4.75 million was already outstanding.

Rate and fee structure Gemino Healthcare Finance, operating as SLR Healthcare ABL, holds a first-priority security interest in substantially all of SOM, LLC's current and after-acquired collateral.